Table 1 Baseline clinical characteristics of BT patients
From: Safety of delivering bronchial thermoplasty in two treatment sessions
BT treatment group | Accelerated | Conventional | p |
|---|---|---|---|
Sample size | 16 | 37 | |
Age (years) | 49.0 (20.8) | 59.0 (19.5) | 0.154 |
Males (%) | 43.8 | 48.6 | 0.660a |
BMI (kg/m2) | 34.0 (10.6) | 29.0 (7.7) | 0.008 |
Tobacco (pack/years) | 0 (7) | 0 (9.5) | 0.938 |
ACQ | 3.5 (1.5) | 3.0 (1.5) | 0.259 |
Exacerbations in 6 months | 2.0 (4.4) | 2.0 (4.0) | 0.868 |
FEV1 (% predicted) | 45.9 (22.1) | 49.5 (26.3) | 0.291 |
FER (%) | 56.0 (24.25) | 51.1 (19.6) | 0.106 |
Change FEV1 post BD (%) | 10.9 (29.5) | 12.5 (22.5) | 0.880 |
Prednisolone (mg/d) | 10.0 (25) | 5.0 (10) | 0.105 |
Inhaled steroids (eq/d) | 2000 (1000) | 2000 (1000) | 0.750 |
SABA (puffs/day) | 12.0 (9) | 8.0 (14) | 0.034 |
Biological therapy (%) | 62.5 | 13.5 | 0.001a |
Bl. Eosinophils (cells/μl) | 50 (100) | 200 (400) | 0.003 |
IgE (I.U.) | 40 (140) | 67 (156) | 0.330 |